Bronchodilator and anti-inflammatory therapy of chronic obstructive pulmonary disease from the position of interchangeability

The choice of drugs used to treat patients with chronic obstructive pulmonary disease (COPD) (inhaled β-agonists, M-anticholinergic drugs, inhaled corticosteroids (ICS)) in view of their interchangeability is reviewed in this article. This aspect is especially important for clinicians when choosing an effective and safe treatment for COPD and for increasing patient adherence to treatment.

The aim of this study was to assess the ratio of the number of reference (original), interchangeable, and generic drugs used in COPD.

Methods. In accordance with the Russian clinical guidelines 2018 and GOLD 2019, modern drugs for the treatment of COPD with bronchodilator and anti-inflammatory activity were selected. All trade names of the corresponding drugs for each international non-proprietary name (INN) In the State Register of Medicines website were considered. The information on the availability of reference (original) drugs and the corresponding interchangeable products, as well as their presence in the List of vital and essential drugs was analyzed.

Results. A large number of generic prodcuts are registered in the State Register of Medicines, and only a few of them are interchangeable with the corresponding reference (original) drug.

Conclusion. The analysis will help widen the doctors’ choice of interchangeable drugs in treatment of COPD with an equivalent effect and safety of reference drugs, as well as to increase the patients’ adherence to treatment.

1. Koval’skaya G.N., Mikhalevich E.N. [Reference and interchangeable medicinal products in the State Register of Medicines]. Russkiy meditsinskiy zhurnal. 2019; 8 (1): 65–69. Available at: https://www.rmj.ru/articles/klinicheskaya_farmakologiya/Referentnye_i_vzaimozamenyaemye_lekarstvennye_preparaty_v_Gosudarstvennom_reestre_lekarstvennyh_sredstv/ (in Russian).

2. World Health Organization. [The top 10 causes of death]. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death [Accessed: December 12, 2020] (in Russian).

3. Russian Respiratory Society. [Chronic Obstructive Pulmonary Disease: Federal Clinical Guidelines]. 2018. Available at: https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf [Accessed: January 5, 2021] (in Russian).

4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINALver1.2-03Dec19_WMV.pdf [Accessed: January 24, 2020].

5. Decramer M.L., Hanania N.A., Lötvall J.O., Yawn B.P. The safety of long-acting β2 -agonists in the treatment of stable chronic obstructive disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 53–64. DOI: 10.2147/COPD.S39018.

6. Kew K.M., Mavergames C., Walters J.A.E. Long-acting beta2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (10): CD010177. DOI: 10.1002/14651858.CD010177.pub2.

7. Voznesenskij N.A. [Formoterol in treatment of bronchial asthma]. Russkiy medicinskiy zhurnal. 2006; 14 (7): 514–517. Available at: https://www.rmj.ru/articles/obshchie-stati/Formoterol_v_lechenii_bronhialynoy_astmy/ (in Russian).

8. Vizel’ A.A. [Indacaterol is a novel 24-h acting bronchodilator for treatment of COPD (literature review)]. Atmosfera. Pul’monologiya i allergologiya. 2011; (4): 65–71. Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles/pulmo/ap_4_2011_65.pdf (in Russian).

9. Arkhipov V.V., Arkhipova D.E., Lazareva N.B. [Novel inhalation devices for treatment of chronic obstructive pulmonary disease]. Pul’monologiya. 2016; 26 (3): 352–356. DOI: 10.18093/0869-0189-2016-26-3-352-356 (in Russian).

10. Zyryanov S.K., Zatolochina K.E., Aseckaya I.L. [A problem of inhaled drug substitutions: an analysis of data from Russian database on adverse events]. Pul’monologiya. 2018; 28 (4): 424–429. DOI: 10.18093/0869-0189-2018-28-4-424-429 (in Russian).

11. Barabanova E.N. [GOLD (2017): what change were made in global strategy of treatment of chronic obstructive pulmonary disease and why?]. Pul’monologiya. 2017; 27 (2): 274–282. DOI: 10.18093/0869-0189-2017-27-2-274-282 (in Russian).

12. Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD002991. DOI: 10.1002/14651858.CD002991.pub3.

13. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI: 10.1136/thx.2011.160028.

14. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD006829. DOI: 10.1002/14651858.CD006829.

15. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029–1036. DOI: 10.1136/thoraxjnl-2012-202872.

16. Janson C., Larsson K., Lisspers K.H., Ställberg B. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroids and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013; 346: f3306. DOI: 10.1136/bmj.f3306.

17. Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD010115. DOI: 10.1002/14651858.CD010115.pub2.

18. Russian Respiratory Society. [Bronchial Asthma: Federal Clinical Guidelines]. 2019. Available at: https://spulmo.ru/upload/kr_bronhastma_2019.pdf [Accessed: April 15, 2019].

19. Vylegzhanina T.G. [New delivery device for inhaled drugs for bronchial asthma treatment. Multidose Easyhaler dry powder inhaler]. Rossiyskiy allergologicheskiy zhurnal. 2014; 11 (2): 37–40. Available at: https://rusalljournal.ru/raj/article/view/509 (in Russian).

20. Papi A., Canonica G.W., Maestrelli P. et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N. Engl. J. Med. 2007; 356 (20): 2040–2052. DOI: 10.1056/NEJMoa063861.

21. Avdeev S.N., Aisanov Z.R., Arkhipov V.V. et al. [The Principles of the Treatment of Mild Asthma: Consistent Guidelines of the Russian Association of Allergology and Clinical Immunology and the Russian Respiratory Society]. Prakticheskaya pul’monologiya. 2017; (1): 82–92. Available at: https://cyberleninka.ru/article/n/printsipy-vybora-terapii-dlya-bolnyh-legkoy-bronhialnoy-astmoy-soglasovannye-rekomendatsii-raaki-i-rro/viewer (in Russian).

22. Ignatova G.L., Belevskiy A.S. [Modern techniques for inhalation drug delivery in the treatment of bronchial obstructive diseases]. Astma i allergiya. 2018; (2): 21–28. Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles/astma/Asthma_2_2018_21.pdf (in Russian).

23. Chikina S.Yu. [Fluticasione furoate/vilanterol combination (Relvar Ellipta®) in bronchial asthma: a review of clinical trials]. Pul’monologiya. 2015; 25 (5): 622–627. DOI: 10.18093/0869-0189-2015-25-5-622-627 (in Russian).

24. Avdeev S.N., Trushenko N.V. [Triple therapy in chronic obstructive pulmonary disease]. Pul’monologiya. 2019; 29 (2): 199–206. DOI: 10.18093/0869-0189-2019-29-2-199-206 (in Russian).

25. Vizel’ A.A., Vizel’ I.Yu., Salakhova I.N., Vafina A.R. [Triple therapy for chronic obstructive pulmonary disease: from analysis to practice]. Farmateka. 2017; (14): 34–41. Available at: https://pharmateca.ru/ru/archive/article/35600 (in Russian).

26. Pasternak E.Yu., Zatolochina K.E., Alyautdin R.N. et al. [Method of spontaneous reports as an instrument controling widely used interchangeable drugs]. Vrach. 2016; (9): 2–5. Available at: https://vrachjournal.ru/ru/25877305-2016-09-01 (in Russian).